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Introduction
In the 1990s, studies on murine leukemia and oncogenes led to 
the recognition of a new member of the hematopoietin receptor super 
family [1-5]. The murine myeloproliferative leukemia (MPL) gene is 
the normal cellular homologue of the oncogene v-MPL and responsible 
for a panmyeloid transformation capacity [1]. This was followed 
by the molecular cloning and charaterisation of MPL, the human 
homologue of the c- and v-MPL [2-4]. The receptor MPL was then 
rapidly recognized as being the thrombopoietin receptor (TpoR) by the 
demonstration that antisense oligonucleotides of c-MPL inhibited the 
colony-forming of megakaryocyte progenitors by Wendling et al. [5]. 
The MPL ligand became the key to the identification of TPO and was 
cloned in 1994 by five independent groups [6-10]. The MPL ligand is 
identical to thrombopoietin and labeled as megakaryocyte growth and 
development factor (MDGF) [9-12]. Human TPO has all the functions 
ascribed to MDGF, and all MDGF-like activity can be neutralized by 
soluble recombinant MPL [13]. TPO stimulates hematopoietic stem 
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Autosomal dominant hereditary Essential Thrombocythemia (ET) due to the gain of function mutation CG 
transversion in the splice donor of intron 3 in the TPO gene on chromosome 3q27 in a Dutch and Polish family is 
associated with marked increased TPO levels and Aspirin-responsive Sticky Platelet Syndrome (SPS). SPS is featured 
by typical clinical manifestations of aspirin responsive microvascular circulation disturbances including erythromelalgia 
and atypical transient ischemic attacks. Increase of large platelets in blood smears and large mature megakaryocytes 
with hyperploid nuclei in a normal cellular bone marrow were diagnostic for autosomal dominant hereditary ET (HET). 
The spectrum of platelet-mediated thrombophilia in HET is comparable to the aspirin responsive SPS in acquired 
JAK2V617F positive ET. The affected members of the Dutch and Polish HET families showed no endogenous erythroid 
colony (EEC) formation. The first generation of the Dutch HET family, two females and one male had stable increased 
platelet counts, no features of PV, no splenomegaly during life-long follow-up. Three of four elderly family members in 
the Dutch HET family developed pancytopenia due to myelofibrosis at the age of 71 and 73 years in two, and evolution 
in acute myeloid leukemia at age 60 in one. These 3 HET patients were on long-term low dose aspirin to prevent 
SPS manifestations and not treated cytoreductive agents indicating that evolution of ET into myelofibrosis (MF) and 
leukemia belong to the natural history of TPO-induced HET. In the congenital HET caused by gain of function mutation 
in the TPO and the JAK2 gene ( JAK2V617I and JAK2R564Q) the responses of mutated CD33 and CD34+ cells to TPO are 
increased, but the responses to EPO were normal thereby explaining why HET caused by heterozygous germline TPO 
and JAK2 mutations are associated with the biological characteristics of ET without PV features.
Figure 1: Thrombopoietine stimultes hematopoietic stem cells and precur-
sors to proliferate, differentiate and mature [13]. Polyploidization takes place, 
Finally, mature megakaryocytes form prothrombocytes (pro-platelets), which 
then disintegrate into platelets, This process takes place in the bone marrow 
sinusoids, but may also occur in the lung capillary bed. Albert E..G.Kr von dem 
Borne et al. 1998 [13].
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cells and megakaryocyte precursors to proliferate, differentiate and 
mature and mature megakaryocytes form pro-platelets, which then 
disintegrate into platelets (Figure 1) [13]. 
Hereditary Essential Thrombocythemia (HET): 
Personal Experiences 
The propositus of the Dutch family with hereditary essential 
thrombocythemia (HET) presented in 1986 with typical erythromelalgia 
complicated by acrocyanosis of a few toes followed by gangrene and 
amputation of toe (Table 1) [14,15]. Recurrent erythromelalgia and 
acrocyanosis in 1986 typically responded to low dose aspirin but 
not to vitamin K antagonist Aspirin responsive platelet-mediated 
microvascular disturbances or Sticky platelet syndrome (SPS) [16] 
was first described by Michiels et al. one year before in 1985 [17] in 
patients with essential thrombocythemia (ET) and polycythemia vera 
(PV).The histopathological findings in bone marrow biopsies of the 
propositus (case II 3, Figure 2) in the Dutch family with HET was 
compatible with ET very similar to the bone marrow findings in our 
patients with acquired ET) and PV complicated by erythromelalgia 
caused by platelet-mediated arteriolar inflammation and thrombosis in 
thrombocythemia [17]. 
The propositus case II3 of the Dutch HET family was referred to Dr 
Michiels at the Erasmus University Medical Center (Academic Hospital 
Dijkzigt Rotterdam) for expert evaluation. At time of diagnosis of 
familial ET the histopathology from bone marrow biopsy material from 
the propositus in 1986 and in 1991 was diagnostic for ET as described 
by Michiels et al. [17] (Figures 3-5). All features according to the 
Rotterdam Clinical and Pathological (RCP) diagnostic criteria for ET 
[17] were present:
1.	 Increase of platelet count in excess of 400 x109/l in the absence 
of any cause or sign of reactive thrombocytosis (Figure 3).
2.	 Typically clustering and increase of enlarged megakaryocytes 
showing mature cytoplasm and hyperploid nuclei in a 
normocellular bone marrow (Figures 4 and 5).
3.	 No preceding or allied other subtype of myeloproliferative 
disorder (MPD) or myelodysplastic syndrome (MDS).
4.	 Normal cellularity of the bone marrow with only slight increase 
of fine reticulin fibers.
Based on the publications in the 1990s on the discovery 
of thrombopoietin (TPO) and its receptor MPL (= TpoR) on 
megakaryocytes and platelets [1-13]. Wiestner et al. [15] discovered in 
1998 that the Dutch HET was caused by a gain of function mutation 
in the thrombopoietine (TPO) gene with the co-segregation of G to 
C in the splice donor site of intron 3 in the TPO gene. This gain of 
function mutation in the TPO gene caused increased TPO levels and 
microvascular manifestations of affected member of the Dutch HET 
family (Figure 2 and Table 1, Dutch HET pedigree) [14,15]. While on low 
dose aspirin since 1986 according to the Rotterdam recommendation 
in 1985 by Michiels et al. [17], all affected HET patients in the Dutch 
family were free of microvascular ischemic circulation disturbances 
and major thrombosis by treatment with low dose aspirin at platelet 
count between 400x109/L and around 1000x109/L during life long 
Clinical data of Dutch HET patients and non-HET subjects HET (%) No HET (%)
Number of cases 10 5
Age years, range 11-58
Vaso-occlusive symptoms: erythromelalgia  (E)           50                                0
Early E, tip paresthesia 30 0
Red congested erythromelalgia 10 0
E complicated by cold tip feeling-arocyanosis/gangrene 20 / 10 0 / 0
Transient ischemic attack: TIA 30 0
Angina pectoris 20 0
Bone marrow histology data of ten HET patiens[14] (%)
Megakaryopoiesis -increased 100
Megakaryocyte clustering of 2-4 cells 100
Erythropoiesis increased 10
Reticulin-content increased grade 1 60
Storage iron present 90
Chromosome abnormalities 0
Note: While on low dose aspirin since 1986 according to Michiels et al. [17], all affected HET patients in the Dutch family were free of microvascular ischemic circulation 
disturbances and major thrombosis at a stable platelet count between 400x109/L and around 1000x109/L during life long follow up without the need of myelosuppressive 
treatment [17,37].
Table 1. Clinical manifestations and main bone marrow histology data in the Dutch family with Sticky Platelet Syndrome in autosomal hereditary essential thrombocythemia 
(HET)[14,15].
Figure 2: Pedigree of the  Dutch family with hereditary essential 
thrombocythemia (HET)[14,15,38]. TPO serum TPO concentrations (pg/ml)from 
the available Dutch family members with autosomal hereditary essential 
thrombocythemia (HET) caused by a gain of function mutation in the TPO 
gene. The numbering of generations and indivuduals in the pedegree is the 
same as in the original publication by Schlemper et al. [14]. Filled in symbols 
affected individuals, open symbols normal individuals. Numbers below 
symbols indicate TPO serum concentrations in pg/ml, the mean of triplicate + 
SEM is given; numbers in italics represent platelet counts x109/L.
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follow up without the need of myelosuppressive treatment. Kondo et 
al. [18] independently described a second HET family and Liu et al. 
[19] a third HET family with a similar gain of function mutation in the 
thrombopoietine (TPO) gene. The laboratory, clinical andbone marrow 
features of the 11 affected family members of the Polish HET family 
are summarized in Table of Figure 6. The serum TPO levels in most 
affected members were increased or even in the upper range of normal. 
Five of eleven affected family members had thrombocythemia related 
symptoms including headaches, acrocyanosis, limb parestahesias, 
venous thrombosis, transient ischemic attacks, miscarriage and 
thrombo-angiitis obliterans consistent with SPS similar as has been 
described in acquired thrombocythemia in ET and PV by Michiels et 
al. [17]. SPS typically responds to low dose aspirin (75 mg/day) and 
attempts to relieve microvascular ischemic symptoms by cytoreductive 
therapy with hydroxyurea in the proposita (PL09) were ineffective. The 
bone marrow histology features in 6 affected members of the Polish 
HET family were similar to early pefibrotic stage of MPN: increase and 
loose to dense clusteringas reflected by normal myeloid to erythroid 
ratio of bone marrow nucleated cells of normal to medium sized mature 
megakaryocytes with normal to slight increased cellularity according to 
age, no increase of erythropoiesis, no increase of reticulin fibrosis (RF 
grade 0 to 1). As compared to controls, the clustered megakaryocytes 
were more compact, of normal to increased size with slightly 
hyperlobulated nuclei, but less pronounced as compared to JAK2V617F 
mutated acquired normocellular ET and prodromal PV (Figure 6).
Molecular Etiology and Pathophysiology of TPO-
Induced Autosomal Dominant HET
Analysis of the TPO gene in his Dutch family with an autosomal 
inherited ET was initiated by us and performed by Dr Skoda [15]. The 
CG transversion in the splice donor of intron 3 of the TPO gene co-
segregated with the affected autosomal dominant hereditary ET (HET) 
in the family. This mutation destroys the splice donor site in intron 3 
and results in exon 3 skipping. The shortened 5’UTR gene resulted in 
a gain of function which leads to overproduction of thrombopoietin 
(TPO) by a mechanism of increased efficiency of the TPO mRNA 
translation. The in vivo increased TPO levels are responsible for the 
etiology of hereditary ET by stimulating megakaryocyte production 
both in vitro and in vivo. Size, number, and mean geometric ploidy 
of megakaryocytes are increased by TPO as compared with other 
cytokines with hematopoietic activity. Evidence for a decisive role of 
deregulated TPO in ET comes from observations in mice overexpressing 
a TPO transgene where increased TPO production resulted in a fatal 
myeloproliferative disorder [20]. Lethally irradiated mice grafted with 
Figure 3: Peripheral blood and bone marrow morphology of HET (1986). 
Peripheral blood smear shows marked thrombocytosis with slight anisocytosis 
and few large platelets, red cells are normocytic. Bone marrow histology 
showed a normocellular hematopoiesis and increase in megakaryocytes with 
loose clustering. There is no increase of granulopoiesis or erythropoiesis. 
The megakaryocytes are usually larger than normal; there are no dysmorphic 
megakaryocytes and there is slight focal reticulin fibrosis grade 1 (WHO: MF 0).
Figure 4: Bone marrow histology of HET (1986). Large megakaryocytes 
with abundant cytoplasm and one cluster of large megakaryocytes with 
hyperlobulated nuclei.
Figure 5: Bone marrow histology 1991.Bone marrow histology is normocellular 
showing slight dyserythropiesis and marked megakaryocytic hyperplasia 
(left). Most megakaryocytes are large with abundant cytplasm (right). One 
dysmorphic megakaryocyte is visible (upper middle).
Figure 6: Clinical laboratory and bone marrow histology features in 6 affected 
members of the Polish (PL) family with autosomal dominant congenital throm-
bocythemia were consistent with early stage pefibrotic Hereditary Essential 
Thrombocythemia (HET) caused by a gain of function mutation in the TPO 
gene (Table). Bone marrow histology showed increase and loose to dense 
clustering of medium sized to large mature megakaryocytes, and normal my-
eloid to erythroid ratio of bone marrow nucleated cells, no to slight increased 
cellularity according to age, no increase of erythropoiesis, and no increase 
of reticulin fibrosis (RF grade 0 to 1). As compared to controls, the clustered 
mature megakaryocytes were more compact, of normal to increased size with 
slightly hyperlobulated nuclei, but less pronounced as compared to acquired 
JAKV617F mutated ET and prodromal polycythemis vera (PV).
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bone marrow cells infected with a retrovirus carrying the murin TPO 
cDNA induced high TPO levels in mice (TPOhigh mice), who developed 
thrombocythemia followed by a lethal myeloproliferative disorder of 
megakaryocytic granulocytic myeloproliferation (MGM) with reduced 
erythropoiesis in the spleen and bone marrow [21]. In this study, 
platelets of normal size and morphology in control mice (A) and large 
platelets in TPOhigh mice were observed initially at time of the ET 
picture [21]. The continuous forced expression of TPO, (TPOhigh mice) 
in mice induces megakaryocyte proliferation and differentiation and 
subsequently develop myelofibrosis [21,22]. TPOhigh mice engineered 
to overexpress TPO in their liver and those that received transplants 
of marrow cells infected with a TPO containing retrovirus develop 
thrombocythemia due to massive hyperplasia of megakaryocytes and 
granulocytes and hypoplasia of erythropoiesis in the bone marrow 
followed by myelofibrosis and extramedullary hematopoiesis within 
2 to 3 months and die from myeloid metaplasia and myelofibrosis 
thereafter [21]. TGF-Beta-1 has been implicated in the pathobiology 
of myelofibrosis by the observation that megakaryocytes from 
TPOhigh rats and mice express high levels of TGF-Beta- in marrow 
extracellular fluids and plasma [22]. Another growth factor produced 
by megakaryocytes, platelet derived growth factor (PDGF), was found 
to be upregulated in a fashion similar to TGF-Beta1. High levels of 
TGF-Beta1 mRNA in bone marrow and spleen cells in TPOhigh mice 
were associated with high levels of TGF-beta1 protein in extracellular 
fluids from these organs [22]. Evolution of ET into transient 
myelofibrosis has been observed in rats receiving recombinant TPO 
[21]. Mice respond to TPO treatment by increasing the number of 
platelets in the circulation and megakaryocytes in the spleen at day 
7 to 10 and returned to pretreatment values at day 14 [22]. In wild 
type mice, TPO treatment increases platelet counts 2.3 fold and the 
number of CFU-megakaryocytes. TPO treatment had profound effects 
on the morphology of megakaryocytes in wild type mice. The overall 
morphology of the megakaryocytes in the spleen became less mature 
as revealed by reduced localization of P-selectin and von Willebrand 
factor on the alpha granules. In addition, a significant portion of these 
megakaryocytes had heavy-electron dense para-apoptotic morphology 
and contained neutrophils embedded in the cytoplasm, as confirmed 
by myeloperoxidase immunostaining. In wild mice TPO treatment 
decreased GATA-1 content in megakaryocytes, and the development 
of myelofibrosis is associated with high levels of transforming growth 
factor beta-1 (TGF-Beta-1) expression in bone marrow and spleen [22]. 
Congenital gain of function mutation in the TPO gene on 
chromosome 3q27 results in increased levels of plasma TPO 
levels, which induce a physiological activation of the TPO→MPL 
signalling pathway. This results in hyperproliferation of large mature 
megakaryocytes (Figure 2) and increased platelet count complicated 
by platelet-mediated microvascular complications (Table 1). Platelets 
do contain many constituents of the TPO signalling machinery. Apart 
from MPL, platelets contain JAK2-PI-3 kinase, Stat-3 and Stat-5 p38, 
MAPK and signalling elements downstream of those regulars [23-27]. 
Platelet stimulation with a supra-physiological plasma concentration of 
TPO initiates aggregation and secretion, illustrating that TPO act as 
an independent inducer of platelet responses [28-30]. Pre-incubation 
of platelet with 20 ng/ml TPO for 5 minutes increases the amount of 
serotonin secretion by low a low dose of the agonist thrombin (0.1 U/
mL) [23]. Activation of platelets induced by TPO and thrombin leads 
to the subsequent activation of the enzyme cPLA2, which liberates 
arachidonic acid from membrane phospholipids, which is the source 
for platelet cyco-oxygenase (COX-1), thereby causing spontaneous 
platelet aggregation with formation of platelet thrombi in the end-
arterial circulation at places of high shear rate consistent with aspirin 
responsive platelet sticky syndrome (SPS) [17,23,30-33]. In addition 
to the activation of platelets free in suspension (plasma) by soluble 
agonist such as thrombin, platelets bind to each other mediated by the 
von Willebrand factor (VWF) as well as to subendotheliam and specific 
surface bound VWF protein that become accessible in the damaged 
vessel wall [23]. Perfusion models mimicking platelet adhesion in 
flowing blood show that platelets (including VWF-platelet aggregates) 
bind to these surface-bound adhesive protein in the absence of a 
soluble platelet activator. Very low concentrations of plasma TPO 
(0.01 to 1.0 ng/mL) enhance this platelet-VWF adhesion and VWF-
platelet aggregation by more than 50%. Adhesion to VWF is preceded 
by a rolling phase until the interaction with VWF is sufficiently 
strong. In the presence of 1 ng/mL TPO, firm platelet attachement 
to subendothelial surface is almost immediate. Subsequently, the 
formation of circulating VWF-platelet aggregates/thrombi mediated by 
the high shear stress occurs, thereby causing platelet thrombi attached 
to the subendothelium appears to be very characteristic for SPS [23]. 
These findings show that increased plasma TPO concentrations causes 
hypersensitive platelets in circulating plasma and thereby have a major 
effect on the initiation of the clinical manifestations of spontaneous 
platelet-mediated arteriolar inflammation and thrombosis at high shear 
rate in the end-arterial circulation including aspirin erythromelalgia 
and its ischemic complications [17] or Sticky Platelet Syndrome16, 
which is preventable by inhibition of platelet cyclo-oxygenase (COX-
1) by low dose aspirin but not by Coumadin (vitamin K antagonist, 
Table 1). The clinical picture of aspirin responsive SPS in HET is 
similar as has been described in 1984/1985 for aspirin responsive 
erythromelalgia caused by arteriolar inflammation and thrombosis in 
the endarteriolar circulation in myelopoliferative thrombocythemia of 
ET and PV patients [17]. Since the discovery of the molecular etiology 
of myeloproliferative neoplasms (MPN), the association of aspirin 
responsive SPS (ASPS) and ET could be confirmed to occur in JAK2V617F 
positive ET, PV, MPL and calreticulin (CALR) mutated ET as well 
[34,35]. Briefly, aspirin responsive microvascular episodes of fainting 
and dizziness typical for ASPS were the predominant clinical feature 
in 23 affected family members of the Dutch and Polish HET families. 
Disease onset in HEToccur already in childhood in patients with HET 
and in adults or eldrly patients in acquired ET and PV. The nature and 
frequencies of aspirin responsive erythromelalgic thrombotic vascular 
manifestations and hemorrhagic events were similar in congenital HET 
and acquired ET [17,34].
Natural History of TPO-Induced Autosomal Dominant 
HET in the Dutch Family
The initial bone marrows histologic findings in the Dutch HET 
family were blindly and independently evaluated in 2014 by Drs 
Piche and De Raeve directly from the pictures without any knowledge 
of the clinical and laboratory data and not aware of the diagnosis of 
congenital familial thrombocythemia caused by a gain of function 
mutation in the TPO gene. The first bone marrow biopsy in 1986 of 
case II3 is consistent with ET according to the 2014 WHO clinical 
molecular and pathological (2014 WHO-CMP, Figures 3 and 4) [35]. 
A second bone marrow biopsy in 1991 showed dense clustering of large 
megakaryocytes megakaryocytes (Figure 5). Bone marrow cellularity is 
normocellular to slightly increased showing slight dyserythropiesis and 
marked megakaryocytic hyperplasia. Most megakaryocytes are large 
with abundant cytplasm with slightly increased reticulin stain grade 1 
(Figure 5). The histology picture of the third follow-up bone marrow 
biopsy in 1996 was dramatically changed (Figures 7 and 8) and showed 
a hypocllular bone marrow with a few focal dense clustered dysplastic 
megakaryocytes and reticulin grade 3 to 4 according to PVSG criteria 
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Ellis et al. [36]. The propositus of the Dutch family with the gain of 
function mutation in the TPO gene showed no further increase of 
platelet counts, no features of PV, no splenomegaly and ultimately 
developed end-stage myelofibrosis at the age of 73 years (Figures 7 and 8).
Bone marrow histology in 4 affected cases at ages between 15 and 
22 years in the third generation of the Polish family showed a slightly 
hypercellular bone marrow due to increased megakaryopoiesis of 
loosely clustered small, medium and some large sized megakaryocytes 
and moderate reactive increase of dispersed mature eosinophils (Figure 
6) [19]. The two adult cases in the second generation of the Polish HET 
family had increase of megakaryopoiesis in a completely normocellular 
bone marrow at ages of 52 and 66 years indicating the absence of bone 
marrow hypercellularity similar as in the proband of the Dutch HET 
case II3 at age 62 years (Figures 3 and 4). All affected members in 
the Polish HET family had normal bone marrow myeloid/erythroid 
cells ratios. whereas the myeloid/erythroid ratio was decreased due 
to an increased erthropoiesis in acquired ET caused by the JAK2V617F 
mutation (Table in Figure 6) [19]. 
In 2010 Posthuma et al. updated the natural history of case II2 and 
II8 of the second generation of the Dutch HET family [37]. Case II 
2 of the Dutch HET family died at the age of 71 due to myelofibrosis 
with severe pancytopenia. Her bone marrow showed myelofibrosis 
with dysplastic megakaryopoiesis, granulopoiesis and erythropoiesis, 
and increase of blasts (10%). The peripheral blood showed 
leukoerythroblastosis, macrothrombocytes, and teardrop cells. She 
died 3 months after diagnosis of myelofibrosis. Case II8 of the Dutch 
HET pedigree had a history of diabetes, hypertension and transient 
ischemic attack in 1989, and was referred in 2008 because of fatigue, 
anemia and fever (hemoglobin 6.1 mmol/L,leukocytes 4.8x109/L, 
platelets 90x109/L, 4% blasts and increased LDH, 1509 U/L [37]. Bone 
marrow cytology showed 45% myeloid blasts (CD34/117/13/33 and 
HLA-DR positive) and complex cytogenetic abnormalities: 47, add(2)
(p2?3, del 5q, i(8((q10) + i (*)(10), -18, -20, i(21)(q10), =2-5 (cp5), and 
no JAK2V617F mutation. The diagnosis was consistent with AML with 
maturation not otherwise classifiable according to WHO criteria. The 
AML was refractory to treatment and the patient died at the age of 71 
years [37]. Patients II2, II8 and III3 of the Dutch HET family were treated 
with low dose aspirin to effectively prevent microvascular ischemic 
attacks including erythromelalgia and did not receive cytoreductive 
agents [17,37]. Consequently, the evolution of normocellular ET into 
myelofibrosis or AML in the second generation at ages around 70 years 
of the Dutch HET family is part of the natural history of polyclonal TPO-
induced HET caused by a gain of function mutation in the TPO gene. 
Increased plasma TPO levels produced by liver cells caused by a gain of 
function mutation in the TPO gene on chromosome 3q27 in the Dutch 
and Polish HET ffamilies do not affect the erythroid and granulocytic 
hematopoietic stem cells but selectively induced proliferation and 
differentiation of polyclonal megakaryopoiesis and platelets leading to 
the disease called hereditary essential thrombocythemia (HET), which 
after life-long follow-up evolved into pancytopenia associated with 
myelofibrosis or blastic transformation of hematopietic stem cells at the 
age around 70 years in the Dutch HET family. 
Pathophysiology of Clinical and Bone Marrow Features 
in Congenital TPO-Induced HET 
The frequencies of aspirin sensitive microvascular circulation 
disturbances (Sticky Platelet Syndrome [16]) were similar in the 
Dutch and Polish HET families. Platelet counts were above 400x109/L 
to around 1000x109/L was associated with normal leukocyte and 
erythrocyte counts, no or slight splenomegaly, and increase of clustered 
large megakaryocytes in a normocellular bone marrow with normal 
myeloloid/erythroid ratio and absence of EEC [34-36]. Kralovics et al. 
compared cMPL expression in the acquired MPDs ET andPV versus 
HET [38]. He examined 44 patients with MPD (23 PV, 15 ET, and 6 MF) 
and 18 healthy individuals. Decreased expression of c-MPL protein was 
found in 30% of patients with PV (7 of 23), 40% of ET (6 of 15) and 
67% of IMF (4 of 6). Thus, c-MPL cannot be used as a diagnostic test 
for PV [38]. To assess whether lower expression of c-MPL is specific 
for MPD Kralovics et al. studied the Dutch HET family in which 
thrombocythemia is caused by elevated TPO serum levels due to a 
splice donor mutation in the TPO gene38. They found lower expression 
of c-MPL protein in 7 of 8 affected HET individuals (88%), despite 
normal c-MPL mRNA levels. These findings could be confirmed in the 
Polish HET family (Table in Figure 6) [19]. Hence, decrease of c-MPL 
protein also can occur in patients who display sustained monolinear 
thrombocythemias (HET) caused by a molecular mechanism different 
from sporadic MPD. Importantly, EECs were negative in all affected 
Dutch and Polish family members indicating the absence of PV features 
at the biological bone marrow level. EECs remain the most reliable 
auxiliary diagnostic assay for PV.
Liu et al. [19] analysed in collaboration with the molecular genetic 
laboratory of Dr Skoda the large Polish and Dutch families with HET 
caused by the identical mutation C→G transversion in the splice donor 
Figure 7: Bone marrow histology of HET (1996). Hypocellular bone marrow 
with decreased granulopoiesis and erythropoiesis, marked peritrabecular 
fibrosis and focal osteosclerosis (left) with increase of dysmorphic 
megakaryocytes (right). Two atypical megakaryocytes with small irregularly 
shaped, hyperchromatic nuclei. (right).
Figure 8: Bone marrow fibrosis in HET (1996). Diffuse and dense reticuin 
fibrosis grade 3 (RF 3) (WHO: MF 2) (Left). Diffuse heavy  increased of 
reticulin fibers with numerous cross-overs  (RF 3) and focal increase of the 
bone trabeculae thickness indicative of osteosclerosis (WHO: MF 2/3).
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in 41 patients of seven Italian families, including 21 ET patients with 
a proven MPLS505N mutation and 20 relatives with thrombocythemia 
reported in the medical records in view of the clinical presentation 
in 30 ET patients with acquired MPL515 mutation (9 males and 21 
females, age 22-84, mean 56 years) [39]. There are at least four distinct 
variants of acquired ET in terms of molecular etiology: acquired 
clonal heterozygous JAK2V617F positive ET, JAK2 wild type clonal ET 
carrying one of the MPL515 or (CALR) mutations [35,39]. All molecular 
variants of acquired clonal ET usually present with aspirin-responsive 
platelet sticky syndrome (ASPS) and frequently show evolution into 
myelofibrosis [35,40]. 
Pathophysiology of Clinical and Bone Marrow Features 
in Congenital JAK2-Induced HET 
There are two novel molecular variants of congenital polyclonal HET 
caused by a gain of function mutation in the JAK2 gene: HET caused 
by a gain of function mutation JAK2V617I and JAK2R564Q in the JAK2 
gene [41-43]. Mead et al. described the germline mutation JAK2V617I 
as the sole genetic abnormality, sufficient to induce the ET phenotype 
of MPN in a family with autosomal dominant HET complicated by 
microvascular ischemic events in some of the them [41,42]. Peripheral 
blood and bone marrow histology are consistent with normocellular 
ET without features of PV [41,42]. The authors demonstrated that 
JAK2V617I is the sole driver in JAK2V617I-positive individuals with 
typical ET peripheral blood and bone marrow features and completely 
normal values for haemoglobin, haematocrit, erythrocytes TPO and 
EPO levels [41,42]. There was a non-significant trend to increased 
(mean 2.4-fold) numbers of phenotypic hematopoietic stem cells 
(HSCs) relative to controls in the JAK2V617Ipositive persons. There were 
no significant differences in the numbers of other myelo-erythroid 
progenitor populations as determined by fluorescence-activated cell 
sorting, in both peripheral blood and bone marrow of the JAK2V617I-
positive ET cases. Compared with controls, however, CFU-GM were 
increased in the BM of JAK2V617I-positive ET cases. BFUEs were not 
affected, in agreement with the lack of erythroid phenotype in these 
patients, whereas CFU-Mks were slightly increased in the BM. After 
stimulation with granulocyte colony-stimulating factor (G-CSF), 
TPO and EPO of peripheral blood CD33+ myeloid and CD34+stem 
and progenitor cells, significant differences in congenital JAK2V617I 
and acquired JAKV617F mutated cells as compared to controls [42]. The 
response to G-CSF was increased in JAKV617I and more prominent in 
JAK2V617F mutated HSC. In signalling and transcriptional experiments 
assays, JAK2V617I showed more activity than wild type JAK2, but 
substantially less than JAK2V617F. After cytokine stimulation, JAK2V5617I 
resulted in markedly increased downstream signalling compared to 
JAK2 wild type and comparable with JAK2V617F. The responses to TPO 
were equally increased in JAK2V617I and JAK2V617F and the response 
to EPO was normal in congenital JAKV617I but increased in acquired 
JAK2V617F. These findings demonstrate that heterozygous congenital 
JAK2V617I mutation induces sufficient cytokine hyperresponsiveness of 
the HSC to induce a homogeneous ET phenotype in blood and bone 
marrow without PV features [42]. In congenital HET caused by the 
heterozygous JAK2V617I mutation the responses to TPO are equally 
increased in germline JAK2V617I and somatic JAK2V617F mutated CD33 
and CD34+ cells , but the responses to EPO are normal in germline 
mutated JAK2V617I and increased in acquired somatic JAK2V617I mutated 
hematopoietic progenitor cells (Figure 10), thereby explaining why 
the heterozygous JAK2V617I germline mutation is associated with ET 
without PV features [42].
Another novel heterozygous JAK2R564Q mutation has been 
identified in another family with autosomal dominant HET [43]. The 
of intron 3 of the THPO gene in 11 affected family members with 
autosomal dominant HET [19]. The megakaryocytes were normal 
medium sized enlarged and strikingly compact and clustered in the 
Polish families with TPO-induced HET caused by the gain of function 
mutation in the TPO gene (Figure 6). The size of megakaryocytes and 
the compactness of their nuclei was significantly higher in HET than in 
normal controls. Similar clinical, laboratory and findings were found 
in acquired ET at that time [17], and recently also in normocellular 
JAK2V617F mutated ET [35]. The TPO receptor (TpoR=MPL) protein 
expression in platelets were down regulated and decreased in the 
Polish and Dutch HET families (Figure 9). The absence of EEC in 
the Dutch and Polish HET families indicates the the erythropoietine 
receptor (EpoR) receptor and its functional status were normal and 
not influenced or activated by the gain of function mutation in the 
TPO gene [19,38]. The decreased MPL expression was associated with 
increased MPL mRNA expression in platelets indicating increased 
MPL receptor protein turn-over metabolism (Figure 9). From these 
basic research studies it can be concluded that increased levels of TPO 
in HET patients are caused by a gain of function mutation in the TPO 
gene, which selectively activates the MPL (TpoR) pathway and not the 
EPO/JAK2 pathway thereby causing ET features with increased platelet 
counts and increase of abnormal polyclonal megakaryocytes arising 
from normal polyclonal hematopoietic hematopoietic stem cells. The 
morphology of large polyclonal megakaryocytes with hyperlobulated 
nuclei in HET caused by the gain of function mutation in the TPO gene 
isquiete similar to the large megakaryocytes in clonal megakaryopoiesis 
of patients with acquired heterozygous JAK2V617F mutated ET are quite 
similar [17,35]. Bone marrow histology in acquired ET complicated 
by aspirin responsive erythromelalgia typically showed increase of 
clustered large mature pleomorphic megakaryocytes with normal 
(<60%, WHO-ET) to increased cellularity (60-80%, prodromal PV) 
due to pronounced increased erytropoiesis [17,35]. EEC and increased 
erythropoiesis in the bone marrow typical for PV were not seen in the 
affected members of the Dutch and Polish HET patients caused by the 
gain of function mutation in the TPO gene (Tables 1 and 2 in Figure 6). 
In a separate study we analysed the clinical and hematological features 
Figure 9: Pedigree of the  Polish  family with hereditary essential 
thrombocythemia (HET)[19]. TPO serum TPO concentrations (pg/ml) platelet 
counts x109/L, MP, serum TPO, MPL mRNA and MPL protein in platelets caused 
by a gain of function mutation in the TPO gene. Filled in symbols (black) are 
affected individuals, and open symbols normal individuals. The affected HET 
patients had incresed platelet counts and serum TPO levels, decreased MPL 
protein content and increased MPL mRNA in platelets indicative for increased 
MPL receptor protein turn-over metabolism and down regulation of the MPL 
receptor on the platelet surface by the increased TPO level.
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growth promoting effects of JAK2R564Q were much milder than those 
of acquired JAK2V617F mutation. The authors found higher levels of 
STAT1 and STAT3 in cells expressing acquired JAK2V617F, compared to 
congenital JAK2R564Q. Total STAT1 levels were increased with acquired 
JAK2V617F and with congenital JAK2R564Q expression as compared to 
wild type JAK2 but this effect was more prominent with the somatic 
JAK2V617F mutation. Platelets were isolated from 3 members of the 
family with the JAK2R564Q mutation and subject to western blot analysis. 
Phosphorylation of JAK2 was increased in the JAK2R564Q-positive 
family members (R564Q1and R564Q2) compared with the father, 
who is negative for the mutation (WT). The growth characteristics 
of the JAK2-expressing cell lines in response to TPO treatment 
were then determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-
dimethyltetrazolium bromide assays. Cells expressing JAK2V617F, either 
with or without JAK2R564Q, were factor-independent, and proliferation 
was significantly increased from wild type JAK2-expressing cells in the 
absence of, and at all concentrations of, TPO. JAK2R564Q-expressing cells 
also showed significantly increased proliferation compared with wild 
type JAK2 cells, although cell proliferation was much less striking than 
with acquired JAK2V617F (Figure 10). An overall increase in downstream 
signaling in mutant JAK2R534Q cells was further demonstrated by 
the upregulated tyrosine-phosphorylation of proteins in germline 
JAK2R564Q-expressing cells as compared to wild type JAK2, and this 
was even more robust in the JAK2V617F-expressing somatic mutants. 
Similar increased signaling was observed in JAK2R564Q-positive patients 
by the demonstration that increased phosphorylation of JAK2 protein 
in platelets isolated from 3 members of the family with the JAK2R564Q 
mutation as compared to a JAK2 wild type family [43]. In the absence 
of TPO, and at all concentrations of TPO, the growth charateristics of 
germline JAK2R564Q-expressing cells also showed significantly increased 
proliferation, compared to JAK2 wild type cells, but this was much less 
striking than with acquired JAK2V617F, thereby confirming the findings 
in JAKV617I HET and explaining why heterozygous JAK2V617I and 
JAK2R564Q are associated with ET without PV features (Figure 10). These 
difference do explain why acquired JAK2V617 mutated ET frequently 
shows features of PV with low serum EPO and increased bone marrow 
cellularity duet o increased erythropiseis (Figure 11) [35,37]. 
Conclusion
 Increased plasma TPO levels produced by liver cells caused by a 
gain of function mutation in the TPO gene on chromosome 3q27 do not 
affect the hematopoetic stem cells but selectively induced proliferation 
and differentiation of polyclonal large megaksaryocytes and large 
platelets leading to the platelet-mediated arterial thrombophilia in 
hereditary essential thrombocythemia (HET) without features of PV. 
While not treated with myelosuppressive agents spontaneous evolution 
of normocellular HET into myelofibrosis in two patients and acute 
myeloid leukemia in a third case at ages around 70 years. Congenital 
HET caused by heterozygous gain of function mutations in the JAK2 
gene is also associated with the clinical picture of ET without any 
feature of PV during long-term follow-up. Acquired JAK2V617F ET 
typically shows features of PV with low serum EPO, the presence of 
EEC and increased erythropioesis and peomorphic megakaryocytes in 
the bone marrow.
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